Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on More
Home>Plug and Play Upstream
Take the Right Path Upstream
Learn More

Contact Us

Introducing our Plug & Play Upstream Development Service for Small-sized Biotechs

Adaptive solutions that help you get from DNA to clinic, the right way for you

You Need to Reach Preclinical Phase? What Now? Article appeared in

Read our article and find out what are the critical steps for small-sized biotechs to get through the preclinical phase quickly and cost-effectively.

Merck Introduces New Integrated Plug & Play Upstream Development Service

Read our press release

Our innovative, custom approach helps small biotechs accelerate their upstream development: Here’s how we do it

Case Study: Accelerate the Time from DNA to Material.
Based on our automated mini-pool approach

Learn how this approach allows to efficiently create, screen and isolate high producing clones with reduced cost and time. Other approaches will be described in this case study, such as cell type selection, expression cassette design and super-transfection.

Fast Track: Accelerate Identification of High-Producing Cell Lines
Based on a multiparallel workflow process

Learn from BDS Team Leader, Cyrielle Corbin, Ph.D. about our mini-pool approach as fast-track process and how we can begin process development in parallel with cell line development, reducing timelines by 10-13 weeks.

Process Development

Our innovative, custom approach helps small biotechs find nimble solutions for their upstream development: Here’s how we do it

Case Study: Increase the Titer of a Difficult to Express molecule
Based on a super-transfection approach

A customer sought to increase the titer of a molecule that had proven difficult to express, with a titer insufficient for clinical studies. Learn how our strategy allowed to increase the titer nearly 4-fold after generation of stable pools.

Straight to the Point: Reaching Clinical Stage Development with a CHOZN® Cell Line
Based on a 200 Liter scale

Learn how our customers reduce cost and time by leveraging our CHOZN® cell line and semi-automated approach to mini-pools and reach a 200L scale.

A service designed around your needs - choose the path that’s right for you

CHOZN® platform

Choose our proprietary CHOZN® platform, which allows for faster, simpler selection and scale-up of high-producing clones.

Right First Time

We help you find the right balance between speed and efficiency, so your clone demonstrates high quality and productivity early on to avoid delays in your clinical trials.

Fast-Track Process

Leverage our innovative approach to mini-pools and confidently run process development and clone selection in parallel and save up to 10 weeks.

Seamless Integration

Run analytical development in parallel to your cell line development to get you progressing faster. Process transfer between our teams is seamless.

One Tailored Suite of Upstream Development Services

A plug & play service offering, exaclty tailored to small-sized biotechs, needing to balance cost, risk and speed to clinic without sacrificing quality

  • Full cell line development services from your molecule of interest to the Research Cell Bank of the clones
  • Validated cell line development process based on mini-pool approach and QA validated limit dilution cloning
  • Variants and signal peptides screening possible during early phases of cell line development
  • Monoclonality reports and stability validation in compliance with regulatory expectations
  • Add-on services for Analytical method development and product characterization
  • Fast-Track process using the mini-pool as early material for process development saving 10-13 weeks on overall project timeline

Ask our Experts

Why is it important to get cell line development right first time?

Learn from BDS Scientist Clémence Justine about factors that must be considered when optimizing recombinant antibody expression.

Generating a high-producing cell line is challenging. How do you make sure to get it right first time on a reduced timeline?

Learn from Research BDS Scientist Lucie Grinders about our mini-pool approach and how we can begin process development in parallel with cell line development.

One advantage of the mini-pool approach is efficiency. How can you further accelerate the process?

Learn from BDS Team Leader, Cyrielle Corbin, Ph.D. how we run steps in parallel for customers who have a very challenging timeline.

What are the advantages of your custom binding assays and how do you do it?

Learn from Senior Scientist Helen Hsu, Ph.D. how, with our custom binding assays, and supported with our comprehensive off-the-shelf Fc gamma receptor binding assays, we optimize your mAb production.

Banner A Molecule’s Journey

Our Experience

Our Experience

BioReliance® End-to-End Solutions

We are an adaptable CDMO partner for start-ups and small biotechs needing to develop and commercialize biologics. We do this by balancing speed, risk and cost through custom solutions, by leveraging our bioprocessing technologies and process development expertise, and by allowing our clients to transfer their process and knowledge to their end point at any step of their drug development. To learn more, please visit BioReliance® End-to-End Solutions - Your CDMO Partner.